Adma Biologics, Inc. (ADMA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-03

Key Insights

Insider Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance, disposed of 20,362 shares of ADMA Biologics, likely to cover tax withholding requirements upon the vesting of restricted stock units (RSUs).
Kestenberg-Messina continues to hold a significant equity stake in ADMA Biologics, including 446,238 shares, as well as unvested RSUs that will vest over the next four years.
The reported transaction appears to be a routine stock disposition to cover taxes and does not indicate a broader trend of insider selling, suggesting the insider remains committed to the company's long-term success.

Want the newest filings?

This analysis covers the filing from 2026-04-03. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play

Get it on Google Play Open in app →

Earlier Insider Trading filings

Filed: 2026-03-09

ADMA Biologics insider Steve Elms has purchased a significant amount of the company's common stock in the past two trading days, acquiring a total of 14,000 shares at an average price of $15.53 per share.
Elms' purchases represent ongoing confidence in ADMA Biologics' prospects, as he is a director and a representative of major shareholder Aisling Capital, which owns over 2 million shares.
The timing of these purchases, just over a month before the end of the fiscal year, could signal that Elms expects positive financial results or other material developments from the company in the near future.

Other reports for Adma Biologics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.